Technical Analysis for RTRX - Retrophin, Inc.

Grade Last Price % Change Price Change
grade C 12.94 0.19% 0.03
RTRX closed up 0.19 percent on Friday, November 15, 2019, on 46 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical RTRX trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Overbought Stochastic Strength 0.00%
Slingshot Bullish Bullish Swing Setup 0.19%
Overbought Stochastic Strength 0.19%
Overbought Stochastic Strength -0.38%
Upper Bollinger Band Walk Strength -0.15%
Overbought Stochastic Strength -0.15%
Doji - Bearish? Reversal 1.33%
Upper Bollinger Band Walk Strength 1.33%
Overbought Stochastic Strength 1.33%

Older signals for RTRX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Retrophin, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orphan drugs for the treatment of rare and life-threatening diseases. The company develops treatments for Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), Duchenne Muscular Dystrophy and other catastrophic diseases. Its products include RE-021, a small molecule angiotensin receptor blocker and selective endothelin receptor antagonist for the treatment of FSGS; and RE-024, a drug that restores the disruption in the biochemical Coenzyme A pathway caused by the non-functioning PANK2 encoded enzyme. The company also develops RE-001, a recombinant fusion protein that substitutes the dystrophin that is lacking in DMD patients; and RE-003, an investigational agent for spinal muscular atrophy. The company was founded in 2011 and is based in New York, New York.
Medicine Biopharmaceutical Medical Genetics Kidney Diseases Muscular Dystrophy Spinal Muscular Atrophy Duchenne Muscular Dystrophy Genetic Genealogy Dystrophy Channelopathies
Is RTRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 26.8
52 Week Low 10.87
Average Volume 468,055
200-Day Moving Average 17.8169
50-Day Moving Average 11.8885
20-Day Moving Average 12.1368
10-Day Moving Average 12.7005
Average True Range 0.4988
ADX 29.46
+DI 21.0175
-DI 11.5314
Chandelier Exit (Long, 3 ATRs ) 11.6936
Chandelier Exit (Short, 3 ATRs ) 12.5364
Upper Bollinger Band 13.4065
Lower Bollinger Band 10.8671
Percent B (%b) 0.82
BandWidth 20.923143
MACD Line 0.2963
MACD Signal Line 0.1638
MACD Histogram 0.1325
Fundamentals Value
Market Cap 496.7 Million
Num Shares 38.4 Million
EPS -1.84
Price-to-Earnings (P/E) Ratio -7.03
Price-to-Sales 6.36
Price-to-Book 3.08
PEG Ratio -1.05
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.36
Resistance 3 (R3) 13.39 13.28 13.29
Resistance 2 (R2) 13.28 13.17 13.27 13.27
Resistance 1 (R1) 13.11 13.11 13.06 13.08 13.24
Pivot Point 13.00 13.00 12.97 12.99 13.00
Support 1 (S1) 12.83 12.89 12.78 12.80 12.64
Support 2 (S2) 12.72 12.83 12.71 12.61
Support 3 (S3) 12.55 12.72 12.59
Support 4 (S4) 12.52